Who is eligible for clinical trial NCT07278609?

Participants must meet protocol criteria for Rheumatic Diseases. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07278609 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-04-27

The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions (NCT07278609)

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

🩺 Plain-English Summary (8th-Grade Level)

The goal of this prospective observational quality improvement study is to determine if a physician tool, MedSafer, combined with educational brochures for patients, can help to reduce the use of 'potentially inappropriate medications' (PIMs) in adults aged 60 and over with rheumatic conditions and polypharmacy (taking 5 or more regular medications). Researchers will follow participants during usual rheumatic disease care. They will compare the rate of PIM deprescribing (stopping medications or reducing the dose) before and after the introduction of the following interventions: * MedSafer reports provided to treating physicians * EMPOWER consumer brochures provided to participants Participants will complete 4 study visits over 18-20 months during which researchers will collect information on medication changes, serious adverse events (emergency visits or hospitalizations), and quality of life.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (3 items).

Location: Montreal General Hospital, McGill University Health Centre — Montreal, Quebec

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Aged ≥60
Followed by a rheumatologist at MUHC for an inflammatory arthritis (such as rheumatoid arthritis, psoriatic arthritis, spondyloarthritis), a systemic autoimmune rheumatic disease (such as systemic lupus erythematosus, inflammatory myositis, systemic sclerosis, antiphospholipid antibody syndrome, Sjogren syndrome, systemic vasculitis), or another chronic musculoskeletal or rheumatic condition (such as crystal arthritis and osteoarthritis)
Currently taking ≥5 regular medications and ≥1 PIM
Anticipated ongoing clinical follow-up in rheumatology at an interval of every 3-9 months

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Unable to provide informed consent
Acute life-threatening illness or life expectancy \<12 months

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Montreal General Hospital, McGill University Health Centre — Montreal, Quebec

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗